1. Home
  2. OPTX vs ACRV Comparison

OPTX vs ACRV Comparison

Compare OPTX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syntec Optics Holdings Inc.

OPTX

Syntec Optics Holdings Inc.

HOLD

Current Price

$2.95

Market Cap

91.6M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.95

Market Cap

95.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPTX
ACRV
Founded
1981
2018
Country
United States
United States
Employees
N/A
78
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.6M
95.0M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
OPTX
ACRV
Price
$2.95
$2.95
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$14.67
AVG Volume (30 Days)
5.6M
570.3K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,900,395.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$1.05
52 Week High
$3.59
$8.00

Technical Indicators

Market Signals
Indicator
OPTX
ACRV
Relative Strength Index (RSI) 64.83 67.52
Support Level $2.80 $2.27
Resistance Level $3.59 $2.59
Average True Range (ATR) 0.43 0.27
MACD 0.12 0.05
Stochastic Oscillator 72.93 60.76

Price Performance

Historical Comparison
OPTX
ACRV

About OPTX Syntec Optics Holdings Inc.

Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: